Article date: 1990/2/2
PubMed ID: 2154034
Journal name: Science (New York, N.Y.) (ISSN: 0036-8075)
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) is an analog of the quinoxalinedione antagonists to the non-N-methyl-D-aspartate (non-NMDA) glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine sites. NBQX protects against global ischemia, even when administered 2 hours after an ischemic challenge.
Author List: Sheardown M J, Nielsen E O, Hansen A J, Jacobsen P, Honoré T
Publication Types: Journal Article
Substances mentioned in the article: Oxadiazoles; Quinoxalines; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, Neurotransmitter; 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; Ibotenic Acid; Aspartic Acid; N-Methylaspartate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Quisqualic Acid; Kainic Acid;
Mesh terms: Animals; Aspartic Acid/analogs & derivatives; Brain Ischemia/drug therapy; Cerebral Cortex/drug effects; Hippocampus/drug effects; Ibotenic Acid/analogs & derivatives; In Vitro Techniques; Kainic Acid/pharmacology; N-Methylaspartate; Neurons/drug effects; Oxadiazoles/pharmacology; Pyramidal Tracts/drug effects; Quinoxalines/metabolism; Quisqualic Acid; Rats; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, Neurotransmitter/drug effects; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid;